Gustavo Viani/sbradioterapia.com.br
Aug 25, 2025, 14:42
Gustavo Viani: A Game Changer in Cervical Cancer RT?
Gustavo Viani, Professor at the Faculty of Medicine of Botucatu, São Paulo State University (UNESP), shared on LinkedIn:
“Can 20 Fractions Compete? A Game Changer in Cervical Cancer RT?
The HYPOCx-iRex Phase II RCT investigated a 44 Gy/20F regimen vs standard 45 Gy/25F in LACC. Here’s what they found
Objective
Compare safety and efficacy of hypofractionated chemoradiation vs conventional RT.
Methods
- n=40, open-label RCT
- IMRT + IGABT + cisplatin
- HYPO arm = 44Gy/20F
- CVRT arm = 45Gy/25F
Results
- OTT: ↓ 39 vs 47 days (P<0.001)
- GI Gr≥3: HYPO 43% vs CVRT 32%
- Para-aortic control at 24 mo: HYPO 100% vs 71% (P=0.003)
- HRQoL ↓ during RT, recovered after
Conclusion
- HYPO is feasible, efficient, and may enhance nodal control. Awaiting long-term data.”
More posts featuring Gustavo Viani.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 14:42
Aug 25, 2025, 14:32
Aug 25, 2025, 14:16
Aug 25, 2025, 14:15
Aug 25, 2025, 13:49
Aug 25, 2025, 12:37
Aug 25, 2025, 12:23